Clinicopathologic significance of putative stem cell marker, CD44 and CD133, in human gastric carcinoma

Journal of Surgical Oncology

Volumn 107, Issue 8, 2013, Pages 799-806

  Chen, Shi ^a   Hou, Jing Hui ^a   Feng, Xing Yu ^a   Zhang, Xiao Shi ^a   Zhou, Zhi Wei ^a   Yun, Jing Ping ^a   Chen, Ying Bo ^a   Cai, Mu Yan ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

CD133; CD44; gastric carcinoma; immunohistochemistry; prognosis

Indexed keywords

CD133 ANTIGEN; HERMES ANTIGEN;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CANCER TISSUE; DISEASE SEVERITY; DISTANT METASTASIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CARCINOMA; SURVIVAL RATE; TUMOR INVASION;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTIGENS, CD; ANTIGENS, CD44; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; NEOPLASTIC STEM CELLS; PEPTIDES; PHENOTYPE; PROGNOSIS; ROC CURVE; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84878328609     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23337     Document Type: Article

References (49)

1. Jemal A, Center MM, DeSantis C, et al.: Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev 2010;19:1893-1907.
2. Bianco R, Melisi D, Ciardiello F, et al.: Key cancer cell signal transduction pathways as therapeutic targets. Eur J Cancer 2006;42:290-294. (Pubitemid 43132883)
3. Wiedmann MW, Caca K: Molecularly targeted therapy for gastrointestinal cancer. Curr Cancer Drug Targets 2005;5:171-193. (Pubitemid 40694859)
4. Nagano O, Saya H: Mechanism and biological significance of CD44 cleavage. Cancer Sci 2004;95:930-935. (Pubitemid 40089583)
5. Ponta H, Sherman L, Herrlich PA: C D44: From adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003;4:33-45. (Pubitemid 36077255)
6. Naor D, Sionov RV, Ish-Shalom D: CD44: Structure, function, and association with the malignant process. Adv Cancer Res 1997;71:241-319. (Pubitemid 27197761)
7. Al-Hajj M, Wicha MS, Benito-Hernandez A, et al.: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003;100:3983-3988. (Pubitemid 36418143)
8. Wheatley SC, Isacke CM: Induction of a hyaluronan receptor, CD44, during embryonal carcinoma and embryonic stem cell differentiation. Cell Adhes Commun 1995;3:217-230.
9. Mani SA, Guo W, Liao MJ, et al.: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-715. (Pubitemid 351636299)
10. Sheridan C, Kishimoto H, Fuchs RK, et al.: CD44+/CD24-breast cancer cells exhibit enhanced invasive properties: An early step necessary for metastasis. Breast Cancer Res 2006;8:R59.
11. Omara-Opyene AL, Qiu J, Shah GV, et al.: Prostate cancer invasion is influenced more by expression of a CD44 isoform including variant 9 than by Muc18. Lab Invest 2004;84:894-907. (Pubitemid 38833249)
12. Li Y, Heldin P: Hyaluronan production increases the malignant properties of mesothelioma cells. Br J Cancer 2001;85:600-607. (Pubitemid 32812030)
13. Yin AH, Miraglia S, Zanjani ED, et al.: AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 1997;90:5002-5012. (Pubitemid 28007217)
14. Miraglia S, Godfrey W, Yin AH, et al.: A novel five-transmembrane hematopoietic stem cell antigen: Isolation, characterization, and molecular cloning. Blood 1997;90:5013-5021. (Pubitemid 28007218)
15. Sagrinati C, Netti GS, Mazzinghi B, et al.: Isolation and characterization of multipotent progenitor cells from the Bowman's capsule of adult human kidneys. J Am Soc Nephrol 2006;17:2443-2456. (Pubitemid 44300960)
16. Sugiyama T, Rodriguez RT, McLean GW, et al.: Conserved markers of fetal pancreatic epithelium permit prospective isolation of islet progenitor cells by FACS. Proc Natl Acad Sci USA 2007;104:175-180. (Pubitemid 46068004)
17. Kordes C, Sawitza I, Muller-Marbach A, et al.: CD133+ hepatic stellate cells are progenitor cells. Biochem Biophys Res Commun 2007;352:410-417. (Pubitemid 44838502)
18. Ito Y, Hamazaki TS, Ohnuma K, et al.: Isolation of murine hairinducing cells using the cell surface marker prominin-1/CD133. J Invest Dermatol 2007;127:1052-1060. (Pubitemid 46625140)
19. Singh SK, Hawkins C, Clarke ID, et al.: Identification of human brain tumour initiating cells. Nature 2004;432:396-401. (Pubitemid 39551674)
20. Ma S, Chan KW, Hu L, et al.: Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 2007;132:2542-2556. (Pubitemid 46890873)
21. Ricci-Vitiani L, Lombardi DG, Pilozzi E, et al.: Identification and expansion of human colon-cancer-initiating cells. Nature 2007;445:111-115. (Pubitemid 46067311)
22. Collins AT, Berry PA, Hyde C, et al.: Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65:10946-10951. (Pubitemid 41713363)
23. Eramo A, Lotti F, Sette G, et al.: Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008;15:504-514. (Pubitemid 351267301)
24. Monzani E, Facchetti F, Galmozzi E, et al.: Melanoma contains CD133 and ABCG2 positive cells with enhanced tumourigenic potential. Eur J Cancer 2007;43:935-946. (Pubitemid 46366698)
25. Curley MD, Therrien VA, Cummings CL, et al.: CD133 expression defines a tumor initiating cell population in primary human ovarian cancer. Stem Cells 2009;27:2875-2883.
26. Hermann PC, Huber SL, Herrler T, et al.: Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007;1:313-323. (Pubitemid 47355323)
27. Smith LM, Nesterova A, Ryan MC, et al.: CD133/prominin-1 is a potential therapeutic target for antibody-drug conjugates in hepatocellular and gastric cancers. Br J Cancer 2008;99:100-109. (Pubitemid 351920235)
28. Boegl M, Prinz C: CD133 expression in different stages of gastric adenocarcinoma. Br J Cancer 2009;100:1365-1366;author reply 1367.
29. Cai MY, Zhang B, He WP, et al.: Decreased expression of PinX1 protein is correlated with tumor development and is a new independent poor prognostic factor in ovarian carcinoma. Cancer Sci 101:1543-1549.
30. Visvader JE, Lindeman GJ: Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-768.
31. Xin HW, Hari DM, Mullinax JE, et al.: Tumor-initiating labelretaining cancer cells in human gastrointestinal cancers undergo asymmetric cell division. Stem Cells 2012;30:591-598.
32. Avital I, Moreira AL, Klimstra DS, et al.: Donor-derived human bone marrow cells contribute to solid organ cancers developing after bone marrow transplantation. Stem Cells 2007;25:2903-2909. (Pubitemid 350127875)
33. Hari D, Xin HW, Jaiswal K, et al.: Isolation of live label-retaining cells and cells undergoing asymmetric cell division via nonrandom chromosomal cosegregation from human cancers. Stem Cells Dev 2011;20:1649-1658.
34. Lugli A, Iezzi G, Hostettler I, et al.: Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer 2010;103:382-390.
35. Gulmann C, Grace A, Leader M, et al.: CD44v6: A potential marker of malignant transformation in intestinal metaplasia of the stomach? An immunohistochemical study using tissue microarrays. Eur J Gastroenterol Hepatol 2003;15:981-986. (Pubitemid 37094297)
36. Heider KH, Dammrich J, Skroch-Angel P, et al.: Differential expression of CD44 splice variants in intestinal- and diffuse-type human gastric carcinomas and normal gastric mucosa. Cancer Res 1993;53:4197-4203. (Pubitemid 24146766)
37. Tahara E: Genetic pathways of two types of gastric cancer. IARC Sci Publ 2004;327-349.
38. Muller W, Schneiders A, Heider KH, et al.: Expression and prognostic value of the CD44 splicing variants v5 and v6 in gastric cancer. J Pathol 1997;183:222-227. (Pubitemid 27436028)
39. Takaishi S, Okumura T, Tu S, et al.: Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells 2009;27:1006-1020.
40. Gunthert U, Hofmann M, Rudy W, et al.: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991;65:13-24. (Pubitemid 121001209)
41. Okayama H, Kumamoto K, Saitou K, et al.: CD44v6, MMP-7 and nuclear Cdx2 are significant biomarkers for prediction of lymph node metastasis in primary gastric cancer. Oncol Rep 2009;22:745-755.
42. Ishimoto T, Nagano O, Yae T, et al.: CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 2011;19:387-400.
43. O'Brien CA, Pollett A, Gallinger S, et al.: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445:106-110. (Pubitemid 46067310)
44. Fukamachi H, Shimada S, Ito K, et al.: CD133 is a marker of glandforming cells in gastric tumors and Sox17 is involved in its regulation. Cancer Sci 2011;102:1313-1321.
45. Zhao P, Li Y, Lu Y: Aberrant expression of CD133 protein correlates with Ki-67 expression and is a prognostic marker in gastric adenocarcinoma. BMC Cancer 2010;10:218.
46. Ma S, Lee TK, Zheng BJ, et al.: CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008;27:1749-1758. (Pubitemid 351380265)
47. Piao LS, Hur W, Kim TK, et al.: CD133(+) liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma. Cancer Lett 2012;315:129-137.
48. Yu JW, Zhang P, Wu JG, et al.: Expressions and clinical significances of CD133 protein and CD133 mRNA in primary lesion of gastric adenocacinoma. J Exp Clin Cancer Res 2010;29:141.
49. Yasui W, Kudo Y, Naka K, et al.: Expression of CD44 containing variant exon 9 (CD44v9) in gastric adenomas and adenocarcinomas: Relation to the proliferation and progression. Int J Oncol 1998;12:1253-1258. (Pubitemid 28239932)